Program
Fusidic Acid
Also written as “CEM-102”, “sodium fusidate” and “Fusidic Acid 1%”.
Its studies are mostly in Conjunctivitis, Bacterial · Impetigo · Cystic Fibrosis · Osteomyelitis · Cellulitis, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arrevus | 50 open or running | phase 3since Oct 5, 2015 | Jul 28, 2009 | none ahead |
| Aceragen | 10 open or running | phase 2since Nov 29, 2022 | Nov 29, 2022 | none ahead |
| Baxis Pharmaceuticals | 11 open or running | phase 3since Mar 19, 2025 | Mar 19, 2025 | none ahead |
| LEO Pharma | 10 open or running | phase 4since Sep 29, 2009 | Sep 29, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2009First study: phase 2 study in Skin Diseases, BacterialNew to ArrevusArrevus · NCT00948142 · 198 enrolled · United States
- Sep 29, 2009LEO Pharma's first study: phase 4 study in ImpetigoNew to LEO PharmaLEO Pharma · NCT00986856 · 58 enrolled · Norway, Sweden
- Dec 18, 2012Phase 2 study in Prosthetic Joint Infections of HipArrevus · NCT01756924 · 14 enrolled · United States
- Oct 5, 20152 phase 3 studiesArrevus · NCT02570490, NCT02569541
- Sep 23, 2021Phase 2 study in MelioidosisArrevus · NCT05105035 · 125 enrolled · Thailand
- Nov 29, 2022Aceragen's first study: phase 2 study in Cystic FibrosisNew to AceragenAceragen · NCT05641298 · United States
- Mar 19, 2025Baxis Pharmaceuticals's first study: phase 3 study in Conjunctivitis, BacterialNew to Baxis PharmaceuticalsBaxis Pharmaceuticals · NCT06911424 · 400 planned · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Elongation factor G inhibitor; Elongation factor G inhibitor”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06911424Conjunctivitis, Bacterial · United States | 3 | Recruiting | Baxis Pharmaceuticals | Mar 16, 2026 | 400 |
| NCT05641298Cystic Fibrosis · United States | 2 | Withdrawn | Aceragen | Sep 2023 | 0 |
| NCT05105035Melioidosis · Thailand | 2 | Completed | Arrevus | Oct 10, 2023 | 125 |
| NCT02570490Cellulitis · United States, Puerto Rico | 3 | Completed | Arrevus | Nov 2016 | 716 |
| NCT02569541Osteomyelitis · United States | 3 | Completed | Arrevus | Oct 17, 2017 | 30 |
| NCT01756924Prosthetic Joint Infections of Hip · United States | 2 | Terminated | Arrevus | Jul 2014 | 14 |
| NCT00986856Impetigo · Norway, Sweden | 4 | Terminated | LEO Pharma | Mar 2005 | 58 |
| NCT00948142Skin Diseases, Bacterial · United States | 2 | Completed | Arrevus | Mar 2010 | 198 |
How it is read
Names in the registry
- “CEM-102”, 3 entries
- “sodium fusidate”, 2 entries
- “Fusidic Acid 1%”, 1 entry
- “Fucidin® cream”, 1 entry
- “ARV-1801”, 1 entry
Codes read as this program: ARV1801.
Conditions, from the studies’ own filings
- Conjunctivitis, Bacterial, 1 study
- Impetigo, 1 study
- Cystic Fibrosis, 1 study
- Osteomyelitis, 1 study
- Cellulitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.